Pretransplant Sensitization and Outcomes Across Isolated Heart, Heart-Kidney, and Heart-Liver Transplantation.
Nov 10, 2026DOI: 10.1016/j.cardfail.2026.11.008Journal ArticleJCF
Written by: Kazuhiro UenoDevon KelleyJessica DominicPavan Atluri
BACKGROUND: High pretransplant sensitization, assessed by calculated panel-reactive antibody (cPRA), is a recognized immunologic risk factor in heart transplantation. Whether its significance differs across isolated heart transplantation (HT), simultaneous heart-kidney transplantation (SHKT), and combined heart-liver transplantation (CHLT) remains unclear.METHODS: Using the UNOS thoracic registry, we identified adult primary isolated HT, SHKT, and CHLT recipients from January 2015 to June 2024. High sensitization was defined as cPRA ≥50%. Outcomes included rejection, 1-year graft failure, and 1- and 3-year mortality. Multivariable analyses were cohort-specific.RESULTS: Among 20,085 isolated HT, 2,045 SHKT, and 342 CHLT recipients, high cPRA was present in 9.8%, 11.7%, and 18.1%, respectively. High cPRA was associated with treated rejection within 1 year after isolated HT (adjusted OR, 1.25; 95% CI, 1.09-1.43) and rejection before discharge after SHKT (adjusted OR, 1.87; 95% CI, 1.18-2.96). High cPRA was also modestly associated with 3-year mortality after isolated HT (adjusted HR, 1.15; 95% CI, 1.01-1.31), but was not associated with 1-year graft failure or mortality in any group. No significant association with rejection, graft failure, or mortality was observed after CHLT. Interaction testing did not show significant effect modification.CONCLUSIONS: The clinical significance of pretransplant sensitization varied by transplant type, outcome, and follow-up horizon. High cPRA identified rejection-related risk after isolated HT and SHKT and a modest longer-term mortality signal after isolated HT, supporting a context-dependent interpretation of cPRA in isolated and multi-organ heart transplantation.